Quoin Pharmaceuticals Ltd ADR Dossier
Qualitative Analysis
Business overview
Quoin Pharmaceuticals Ltd. (NASDAQ: QNRX) is a late clinical-stage specialty pharmaceutical company focused on developing and commercializing therapeutic products that treat rare and orphan diseases. The company's lead product candidate is QRX003, a once-daily topical lotion formulated with proprietary Invisicare technology. QRX003 is designed to treat Netherton Syndrome, a rare and severe genetic skin disorder characterized by a compromised skin barrier and chronic inflammation. Quoin is also developing QRX009, a topical rapamycin platform targeting rare dermatological indications such as Pachyonychia Congenita, Gorlin Syndrome, and Tuberous Sclerosis Complex.
Research as of 20 Jun 2026
Strategic Initiatives
Growth programs, investments, and their expected impact
Establishing direct commercialization capabilities in core markets (United States, Western Europe, and Japan) to self-commercialize QRX003 and other pipeline products upon regulatory approval [1.1.2].
Expected impact: Maximizes long-term commercial margins and maintains direct control over marketing and distribution in key global territories.
Securing out-licensing and distribution agreements for QRX003 in territories outside of the core self-commercialization markets.
Expected impact: Expands global reach to 61 countries through nine established partnerships, covering regions such as Canada, Australia/New Zealand, China, and the Middle East.
Mergers, Acquisitions & Partnerships
Recent deals and strategic collaborations
Strategic Partnerships
Facilitates the commercialization and distribution of QRX003 in Saudi Arabia and other Middle East and North Africa (MENA) countries [2.4.3].
Terms: Genpharm has exclusive royalty-free rights to commercialize the product in the MENA region, and Quoin is entitled to a revenue-sharing arrangement on net sales.